Table 1.

Growth inhibition of human WT EGFR tumor cell lines and xenografts sensitive or insensitive to erlotinib

NSCLC cell lineEGFR genotypeMaximal inhibition (%)EC50 (μmol/L)TGI significance (rmANOVA)Median %TGI, day 15Classification
H292WT720.1P < 0.000185Sensitive
H322WT800.4ndndSensitive
H358WT750.6P = 0.007325Sensitive
H441WT552P = 0.000260Sensitive
Calu3nd780.6nd67Sensitive
A427WT622ndndSensitive
A549WT445P = 0.513149Intermediate
Colo699nd453ndndIntermediate
H2122WT455nd44Intermediate
H460WT295P = 0.98236Insensitive
Calu6WT36>10P = 0.58840Insensitive
H1703WT307ndndInsensitive
SW1573WT259ndndInsensitive
H1437nd5>10ndndInsensitive
H1299WT255ndndInsensitive
Hop92WT225ndndInsensitive
H23WT305ndndInsensitive
  • NOTE: Inhibition was assessed by two efficacy measurements, % maximal growth inhibition in vitro and statistically significant [repeated measures ANOVA (rmANOVA)] tumor growth inhibition (TGI) in xenografts treated with erlotinib (100 mg/kg, qd) or vehicle for 14 days, and one potency measurement, EC50, the micromolar concentration required for half-maximal inhibition in vitro. Sensitivity was defined as >50% in vitro growth inhibition at an erlotinib concentration of <5 μmol/L, with statistically significant tumor growth inhibition if available.